The Belrise Industries IPO witnessed frenzied investor interest, with a 41.3x subscription. However, the Grey Market Premium (GMP) has fallen 25% after allotment. With the stock set for its listing on May 28, 2025, retail and institutional investors alike are wondering — will Belrise provide the listing pop they were hoping for?
Overview: A High-Octane IPO With a Speed Bump
Belrise Industries Ltd., which is a top Tier-1 auto component supplier, came out with its IPO with much pomp and show and high anticipation. With the price band being fixed at ₹85–₹90 and the fresh issue size of ₹2,150 crore, the issue witnessed humongous demand across all investor categories.
The offer was oversubscribed 41.3 times, with Qualified Institutional Buyers (QIBs) subscribing more than 92 times, and Non-Institutional Investors (NIIs) subscribing 54.5 times. Even the retail portion got subscribed more than 15 times, indicating frenzy interest from all sides of the investment community.
But now, once the IPO allotment had been finalized, the Grey Market Premium (GMP) — a telling pre-listing sentiment indicator — has dropped by almost 25%, from ₹23 to approximately ₹17. This has questioned critical questions: Will the stock still list at a premium? Or has the momentum run out before the finish line?
GMP: From Red-Hot to Cautiously Warm
GMP is basically the additional premium investors are ready to pay per share in the unofficial market prior to its listing. For Belrise, GMP had risen during the IPO period with investors hopeful of sound fundamentals and ambitious growth strategies.
But as the allotment finished, GMP experienced a smooth drop — a common, but not across-the-board, pattern following oversubscription when speculative demand evaporates and profit-taking takes place in the off-the-record market.
The Reasons for the Fall:
- Market Volatility:
The wider market has seen fluctuations of late, with tensions on the global diplomatic front and volatile oil prices scaring off investors worldwide. That fear can spill into grey market sentiment. - Fears of Overvaluation:
A few analysts think that the higher part of the price band already incorporates most of the growth in the future, resulting in apprehensive investors taking a step back. - Profit-Booking in Grey Market:
Allottees and grey market players tend to book short-term gains after allotment, lowering GMPs temporarily. - Liquidity Tightening:
With a succession of IPOs making their way to the market in recent times, investor liquidity can be thin, which has implications for demand in the illegal markets.
Belrise Industries: Business Overview
Belrise Industries is a domestic major auto component company, previously known as Badve Engineering Ltd. With 25 years of experience, the company manufactures key components such as chassis systems, polymer components, exhaust systems, and suspension modules for two-wheelers, passenger cars, and commercial vehicles.
Strategic Strengths:
- 15 factories spread over 8 states.
- Diversified customer base comprising Bajaj Auto, Hero MotoCorp, Honda Motorcycle & Scooter India, Royal Enfield, and Jaguar Land Rover.
- International operations and exports to Europe and Southeast Asia.
- Investments in electric vehicle (EV) compatible components.
In a business that requires precision, scale, and on-time delivery, Belrise has proven itself to be a trustworthy partner, closely embedded in its customers’ supply chains — a fact that meaningfully de-risks its revenue model.
Financial Performance: A Strong Track Record
- FY24 Revenue: ₹7,484.24 crore (up 13.7% YoY)
- FY24 Net Profit: ₹310.88 crore
- Q1 FY25 Revenue: ₹1,424.73 crore
- Q1 Net Profit: ₹65.83 crore
The company has reported consistent top-line and bottom-line growth, with expanding profit margins and cost savings. EBITDA margins have hovered between 10–12%, indicating operating discipline and scale economics.
IPO Aims and Uses of Proceeds
The IPO is a 100% fresh issue, without any Offer for Sale (OFS) component. Here’s what the company intends to do with the proceeds:
- ₹1,618 crore would be used towards repayment or prepayment of outstanding loans. This should also lower interest expenses substantially and enhance debt-equity levels.
- The balance would be utilized for general corporate purposes, expansion plans, and even to finance new R&D initiatives in electric mobility.
This turns the IPO into a balance sheet clean-up and growth enabler — a great message to long-term investors.
Analyst Commentary: What the Experts Say
Though the GMP correction is not favorable for short-term speculators, market experts opine long-term fundamentals are still intact.
“GMP is not always a good predictor of listing gains. Belrise’s fundamentals are solid, its client base is sticky, and the industry tailwinds — especially from EV adoption — are in its favor,”
said Ankit Desai, VP of Research at Axis Securities.
Another analyst at one of the leading brokerages said:
“A decline in GMP is normal after allotment. What one should worry about is post-listing performance, which is more influenced by quarterly performance and sector momentum.”
What Should Investors Do?
For investors who are allotted shares:
- Hold on if your time horizon is 6–12 months or longer.
- Observe the first-day close of the stock and its behavior in the first week for indications of institutional patronage.
For investors who are not allotted:
- Wait out listing and evaluate volume trends before leaping in.
- Look to enter on a dip if fundamentals are still sound and broader markets firm up.
Conclusion: Short-Term Blip or Long-Term Opportunity?
The 25% drop in Belrise Industries’ GMP is a reminder that IPO investing isn’t all about hype — it’s about homework. Sure, some of the initial euphoria has blown off, but the underlying fundamentals of the business are still sound.
Belrise is a debt-reduction tale of robust OEM relationships, scalable operations, and attractive exposure to the EV value chain. For long-term investors, it might as well be a value-unlocking saga in the making..
As the stock makes it to the bourses, everyone will be watching its listing price and first-day performance. But for the patient, Belrise could still lead the way — even if its starting wasn’t quite so thunderous as planned.
Feel free to ask for:
- A research report one-pager,
- A classroom-ready PowerPoint presentation, or
- This report translated into Hindi or Marathi.
